Cargando…
Iron therapy for renal anemia: how much needed, how much harmful?
Iron deficiency is the most common cause of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in end-stage renal disease (ESRD) patients. Iron deficiency can easily be corrected by intravenous iron administration, which is more effective than oral iron supplementation, at least in adult...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805051/ https://www.ncbi.nlm.nih.gov/pubmed/17206511 http://dx.doi.org/10.1007/s00467-006-0405-y |